- Home
- IMPP vs ACRS Comparison
IMPP vs ACRS Comparison
Compare IMPP & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- ACRS
- Stock Information
- Founded
- IMPP 1981
- ACRS 2012
- Country
- IMPP Greece
- ACRS United States
- Employees
- IMPP N/A
- ACRS N/A
- Industry
- IMPP Marine Transportation
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- ACRS Health Care
- Exchange
- IMPP Nasdaq
- ACRS Nasdaq
- Market Cap
- IMPP 119.7M
- ACRS 132.0M
- IPO Year
- IMPP N/A
- ACRS 2015
- Fundamental
- Price
- IMPP $3.48
- ACRS $2.05
- Analyst Decision
- IMPP
- ACRS Hold
- Analyst Count
- IMPP 0
- ACRS 4
- Target Price
- IMPP N/A
- ACRS $1.00
- AVG Volume (30 Days)
- IMPP 149.3K
- ACRS 1.3M
- Earning Date
- IMPP 11-26-2024
- ACRS 11-06-2024
- Dividend Yield
- IMPP N/A
- ACRS N/A
- EPS Growth
- IMPP N/A
- ACRS N/A
- EPS
- IMPP 1.69
- ACRS N/A
- Revenue
- IMPP $147,505,660.00
- ACRS $27,079,000.00
- Revenue This Year
- IMPP N/A
- ACRS N/A
- Revenue Next Year
- IMPP $36.53
- ACRS N/A
- P/E Ratio
- IMPP $2.06
- ACRS N/A
- Revenue Growth
- IMPP N/A
- ACRS 26.35
- 52 Week Low
- IMPP $1.44
- ACRS $0.77
- 52 Week High
- IMPP $4.59
- ACRS $2.72
- Technical
- Relative Strength Index (RSI)
- IMPP 31.17
- ACRS 55.69
- Support Level
- IMPP $3.42
- ACRS $2.09
- Resistance Level
- IMPP $3.56
- ACRS $2.72
- Average True Range (ATR)
- IMPP 0.09
- ACRS 0.26
- MACD
- IMPP -0.01
- ACRS -0.01
- Stochastic Oscillator
- IMPP 16.22
- ACRS 40.71
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil and jet fuel, as well as edible oils and chemicals.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.